1. Safety and efficacy of NEPA and dexamethasone in Hodgkin's lymphoma patients: a single-center real-life experience
- Author
-
Zilioli, V, Muzi, C, Minga, P, Codega, P, Crucitti, L, Meli, E, Esposito, A, Panico, C, Rusconi, C, Cairoli, R, Zilioli V, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, Cairoli R, Zilioli, V, Muzi, C, Minga, P, Codega, P, Crucitti, L, Meli, E, Esposito, A, Panico, C, Rusconi, C, Cairoli, R, Zilioli V, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, and Cairoli R
- Abstract
We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin's lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug-drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.
- Published
- 2020